To learn more about how companies can improve their understanding and forecasting of generic competition, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/generic_myths.pdf
"The Five Myths of Generic Competition" is part of Pharma Matters, a quarterly report series from Thomson Reuters that covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Newport Vision Premium(TM), Thomson Pharma(R), and the Thomson Messaging Mapping System(SM).
To sign up for the Thomson Reuters Pharma Matters series of publications visit:
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.
|SOURCE Thomson Reuters|
Copyright©2009 PR Newswire.
All rights reserved